A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

NCT05668572 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

12000

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Papillomavirus Infection

Interventions

BIOLOGICAL: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
BIOLOGICAL: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）

Sponsor

Beijing Health Guard Biotechnology, Inc